Delivery Order SPE2DB22D1106-SPE2DB25FEPB8
Award Date
5/19/25
Potential Completion Date
5/20/25
Potential Value
$3.4K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, under a Delivery Order with a Firm Fixed Price pricing type. The contract has a ceiling value of $2,365.92 and an ultimate completion date of August 23, 2024. The contract is not set aside for any specific business category. Amerisourcebergen has been...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $16,849.60 and is a Firm Fixed Price Delivery Order, awarded to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of May 14, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has a ceiling value of $7,664.20 and an ultimate completion date of November 15, 2023. This is a firm fixed-price delivery order contract, and there is no set-aside designation. Amerisourcebergen Drug Corp holds a significant...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $1,577.28, was awarded to AmerisourceBergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of April 17, 2024. AmerisourceBergen Drug Corp...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $1,182.96, was awarded to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, particularly the Department of Defense (DoD) and Veterans Affairs (VA) healthcare systems. The contract is a Delivery Order under a larger...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccines to the Defense Logistics Agency (DLA). The contract, valued at $69,524.40, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of September 11, 2024. The contract is not designated with a set-aside requirement, indicating open competition....
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a total ceiling value of $4,212.40. The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of May 7, 2025. The contract is not set aside for any particular business type....
The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products. The delivery order, valued at $2,365.92, has a completion date of February 23, 2024. AmerisourceBergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) awarded by DLA, valued up to $999,999,999.00 with a...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the U.S. Defense Department's Medical Supply Chain. The contract, valued at $3,154.56, was awarded to Amerisourcebergen Drug Corp, a subsidiary of the Amerisourcebergen Corporation, one of the largest pharmaceutical distribution companies in the world. This is a Delivery Order contract with a Firm Fixed Price pricing type, and the ultimate completion date is June 7, 2024....
The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4564161164 HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products. The ceiling value of this delivery order is $3,943.20, with a performance period through April 4, 2024. This award is not associated with any set-aside designation. AmerisourceBergen Drug Corp is the prime contractor and...